Abstract: Circuits, devices and methods are disclosed, including a phase shifter comprising a first node and a second node, and a first transmission line element having an inductance and a variable capacitance on each side of the inductance, the variable capacitance configured to provide a plurality of capacitance values to yield corresponding phase shift values based on an increment having a magnitude that is less than 90 degrees. In some implementations, the phase shifter further comprises a second transmission line element in series with the first transmission line element, the second transmission line element having an inductance and a variable capacitance on each side of the inductance configured to extend an overall phase shift range provided by the phase shifter.

Abstract: The invention relates to novel polymers containing one or more 3,7-dialkyl-benzo[1,2-b:4,5-b?]dithiophene repeating units, methods for their preparation and monomers used therein, blends, mixtures and formulations containing them, the use of the polymers, blends, mixtures and formulations as semiconductor in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers, blends, mixtures or formulations.

Abstract: The invention relates to novel polymers containing repeating units based on benzo[1,2-d;4,3-d?]bisthiazole, monomers and methods for their preparation, their use as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers.

Abstract: Disclosed are systems and method for controlling frequency synthesizers. A control system can be implemented in a phase-locked loop (PLL), such as a Frac-N PLL of a frequency synthesizer, to reduce or eliminate reference spurs. In some embodiments, such a control system can include a phase detector configured to receive a reference signal and a feedback signal. The phase detector can be configured to generate a first signal representative of a phase difference between the reference signal and the feedback signal. The control system can further include a charge pump configured to generate a compensation signal based on the first signal. The control system can further includes an oscillator configured to generate an output signal based on the compensation signal. The compensation signal can be configured to reduce or substantially eliminate one or more reference spurs associated with the frequency synthesizer.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Disclosed are circuits and method for reducing or eliminating reference spurs in frequency synthesizers. In some implementations, a phase-locked loop (PLL) such as a Frac-N PLL of a frequency synthesizer can include a phase frequency detector (PFD) configured to receive a reference signal and a feedback signal. The PFD can be configured to generate a first signal representative of a phase difference between the reference signal and the feedback signal. The PLL can further include a compensation circuit configured to generate a compensation signal based on the first signal. The PLL can further includes a voltage-controlled oscillator (VCO) configured to generate an output signal based on the compensation signal. The compensation signal can include at least one feature for substantially eliminating one or more reference spurs associated with the PLL.

Abstract: The present invention relates to a novel polycyclic polymer comprising fused thiophene units. The present invention also relates to a method for producing such polymer as well as the use of such polymer, particularly in organoelectronic applications.

Abstract: A method and system provide a complete energy analytical model. An input model is acquired and consists of a combination of architectural building elements (ABEs) and conceptual massing elements (CMEs). The input model is pre-processed by extracting information from both the ABEs and the CMEs, and constructing virtual elements that encapsulate the extracted information. A discrete set of points in three-dimensional (3D) space that is distributed over boundary faces of the ABEs or CMEs is determined. The discrete set of points is used to provide a representation of the input model that is used in combination with a 3D cubical grid (a voxel grid) to analyze a spatial structure of the input model. A two-dimensional (2D) discrete approximation of the geometry of the input model is used to determine surfaces of the energy analytical model which is then output.

Abstract: The invention relates to novel phenanthro[1,10,9,8-c,d,e,f,g]carbazole polymers, methods and materials for their preparation, their use as semiconductors in organic electronic (OE) devices, and to OE devices comprising these polymers.

Abstract: The invention relates to novel conjugated polymers containing one or more diindeno-thieno[3,2-b]thiophene based polycyclic repeating units, to methods for their preparation and educts or intermediates used therein, to polymer blends, mixtures and formulations containing them, to the use of the polymers, polymer blends, mixtures and formulations as organic semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these polymers, polymer blends, mixtures or formulations.

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described; which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: A dressing is presented comprising a base portion and at least one flap connected to the base portion; the base portion comprising an adhesive subject contacting surface; the at least one flap comprising an adhesive surface and being adapted to be repositioned over a first edge of the dressing; wherein during use the base portion is fixed to the skin of a subject beneath a cannula inserted into the subject at an insertion point such that the first edge faces the insertion point, and the at least one flap is repositioned over the first edge and the inserted cannula and fixed to the skin of the subject to secure the cannula to the subject. Methods of applying the dressing and kits comprising the dressing are also presented.

Abstract: The invention relates to benzo[h]benz[5,6]acridino[2,1,9,8-klmna]acridines, methods of their preparation, their use as semiconductors in organic electronic (OE) devices, and to OE devices comprising them.

Abstract: The invention relates to novel polymers containing repeating units based on benzodithiophene or derivatives thereof, monomers and methods for their preparation, their use as semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers.

Abstract: Disclosed are circuits and method for reducing or eliminating reference spurs in frequency synthesizers. In some implementations, a phase-locked loop (PLL) such as a Frac-N PLL of a frequency synthesizer can include a phase frequency detector (PFD) configured to receive a reference signal and a feedback signal. The PFD can be configured to generate a first signal representative of a phase difference between the reference signal and the feedback signal. The PLL can further include a compensation circuit configured to generate a compensation signal based on the first signal. The PLL can further includes a voltage-controlled oscillator (VCO) configured to generate an output signal based on the compensation signal. The compensation signal can include at least one feature for substantially eliminating one or more reference spurs associated with the PLL.

Abstract: A corrugated shipping container having an elongated container body with an open end, and a lid to cover the open end. The lid and container have a through-lid grip opening and one or more through-lid locking ports for locking the lid to the container body with a cable tie. The through-lid grip opening is configured with an ergonomic profile to improve the lifting, handling and carrying of the shipping container, particularly when weighed with shipping articles, such as a golf bag and set of golf clubs.